Kura Oncology, Inc. (NASDAQ:KURA) Shares Purchased by 1492 Capital Management LLC

1492 Capital Management LLC boosted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 25.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 429,746 shares of the company's stock after buying an additional 87,148 shares during the period. Kura Oncology accounts for about 1.5% of 1492 Capital Management LLC's investment portfolio, making the stock its 21st biggest holding. 1492 Capital Management LLC owned approximately 0.53% of Kura Oncology worth $2,836,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KURA. Virtus ETF Advisers LLC lifted its holdings in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares during the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Kura Oncology in the 1st quarter valued at $66,000. Flower City Capital acquired a new position in shares of Kura Oncology in the 1st quarter valued at $79,000. Corton Capital Inc. acquired a new position in shares of Kura Oncology in the 4th quarter valued at $99,000. Finally, Optimize Financial Inc acquired a new position in shares of Kura Oncology in the 4th quarter valued at $100,000.

Kura Oncology Price Performance

Kura Oncology stock traded down $0.24 during midday trading on Friday, reaching $6.23. The company had a trading volume of 924,362 shares, compared to its average volume of 1,409,765. The company has a market capitalization of $539.33 million, a P/E ratio of -2.97 and a beta of 0.40. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $21.60. The firm's fifty day simple moving average is $6.16 and its 200-day simple moving average is $6.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.07 and a quick ratio of 8.07.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on KURA. Mizuho cut their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, May 19th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research report on Monday, April 28th. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a research report on Wednesday, June 4th. Wall Street Zen downgraded Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Finally, Barclays cut their price target on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.